title: [A comparative study on early toxicity of conditioning regimen with or without antithymocyte globulin].
abstract: OBJECTIVE
  To evaluate the toxicity of conditioning regimens of modified Bu/Cy +/- antithymocyte (ATG) in early stage after allogeneic hematopoietic stem cell transplantation (allo-HSCT).
  
  
  METHODS
  A hundred patients with hematological malignancies undergoing allo-HSCT were assessed. Forty-two patients (group A) were conditioned with modified Bu/Cy regimen, 58 (group B) with modified Bu/Cy+ATG regimen. The occurrence of toxicity during the early stage after transplantation was evaluated and compared, including non-infectious fever, diarrhea, hepatotoxicity, mucositis and hematological toxicity.
  
  
  RESULTS
  In group A and B, the incidence of non-infectious fever was 4.8% vs 81.0%, transaminase elevation 59.5% vs 65.5%, bilirubin elevation 16.7% vs 48.3%, diarrhea 59.5% vs 79.3% and mucositis 45.2% vs 37.9%, respectively, white blood cells reached zero occurred at a median of +3 d and -3 d, the rate of red cell and platelet transfusion-dependence, within 10 days before transplantation was 11.9% vs 32.8 and 16.7% vs 82.8%, respectively.
  
  
  CONCLUSIONS
  Significant higher incidence of non-infectious fever, diarrhea, hepatotoxicity, leukopenia, and transfusion dependence is found and considered to be related to the administration of ATG in the conditioning regimen.
authors: Institute of Hematology of Peking University, People's Hospital, Beijing 100044, China.
authors: Dai-hong
authors: DH
authors: Liu
authors: Jing
authors: J
authors: Liu
authors: Kai-yan
authors: KY
authors: Liu
authors: Lan-ping
authors: LP
authors: Xu
authors: Huan
authors: H
authors: Chen
authors: Yu-hong
authors: YH
authors: Chen
authors: Wei
authors: W
authors: Han
authors: Yu
authors: Y
authors: Wang
authors: Xiao-hui
authors: XH
authors: Zhang
authors: Xian-jun
authors: XJ
authors: Huang
mesh_terms: D000293:Adolescent; D000328:Adult; D000961:Antilymphocyte Serum / Q000009:adverse effects* / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D005260:Female; D006086:Graft vs Host Disease / Q000517:prevention & control; D019337:Hematologic Neoplasms / Q000601:surgery; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008297:Male; D008875:Middle Aged; D019172:Transplantation Conditioning / Q000009:adverse effects / Q000379:methods*; D014184:Transplantation, Homologous; D055815:Young Adult
chemical_list: D000961:Antilymphocyte Serum